Advanced search
Publication Cover
mAbs Volume 7, 2015 - Issue 6
Submit an article Journal homepage
3,923
Views
60
CrossRef citations to date
0
Altmetric
Report

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

Philippe GataultService de Néphrologie et Immunologie clinique; CHRU de Tours; France;Laboratoire d'Immunologie; CHRU de Tours; France;EA 4245; Université François-Rabelais de Tours; FranceCorrespondence[email protected]
,
Guillaume BrachetLaboratoire d'Immunologie; CHRU de Tours; France;UMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS
,
David TernantUMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS;Laboratoire de Pharmacologie-Toxicologie; CHRU de Tours; France
,
Danielle DegenneLaboratoire d'Immunologie; CHRU de Tours; France;UMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS
,
Guillaume RéciponLaboratoire d'Immunologie; CHRU de Tours; France
,
Christelle BarbetService de Néphrologie et Immunologie clinique; CHRU de Tours; France
,
Emmanuel GyanUMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS;Service d'Hématologie et Thérapie Cellulaire; CHRU de Tours; France
,
Valérie Gouilleux-GruartLaboratoire d'Immunologie; CHRU de Tours; France;UMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS
,
Cécile BordesCHU de Bordeaux; France; Laboratoire d'Immunologie et d'Immunogénétique; France;Université de Bordeaux; UMR 5164 CIRID; France
,
Alexandra FarrellUMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS
,
Jean Michel HalimiService de Néphrologie et Immunologie clinique; CHRU de Tours; France;EA 4245; Université François-Rabelais de Tours; France
&
Hervé WatierLaboratoire d'Immunologie; CHRU de Tours; France;UMR 7292; Université François-Rabelais de Tours; France;UMR 7292 GICC; CNRS
 show all
Pages 1205-1211 | Received 27 Mar 2015, Accepted 17 Aug 2015, Published online: 26 Sep 2015

References

  • Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33:1389-401; PMID:9171898; http://dx.doi.org/10.1016/S0161-5890(96)00078-8
  • Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria Nat Biotechnol 2007; 25:1256-64; PMID:17989688; http://dx.doi.org/10.1038/nbt1344
  • Burwick RM, Burwick NR, Feinberg BB. Eculizumab fails to inhibit generation of C5a in vivo. Blood 2014; 124:3502-3; PMID:25431478; http://dx.doi.org/10.1182/blood-2014-07-589366
  • Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, et al. The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 2006; 355:1233-43; PMID:16990386; http://dx.doi.org/10.1056/NEJMoa061648
  • Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K,. Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome. N Engl J Med 2013; 368:2169-81; PMID:23738544; http://dx.doi.org/10.1056/NEJMoa1208981
  • Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013; 162:62-73; PMID:23617322; http://dx.doi.org/10.1111/bjh.12347
  • Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 2014; 63:40-8; PMID:24021908; http://dx.doi.org/10.1053/j.ajkd.2013.07.011
  • Editor MBH. Health chiefs refuse to pay for lifesaving kidney treatment [Internet]. The Times. [cited 2014 Aug 3]. Available at: http://www.thetimes.co.uk/tto/health/news/article3775905.ece
  • Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, et al. Dynamics of complement activation in atypical HUS and how to monitor eculizumab therapy. Blood 2014; 124: 1715-26; PMID:25037630; http://dx.doi.org/10.1182/blood-2014-02-558296
  • Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, et al. Genetic Variants in C5 and Poor Response to Eculizumab. N Engl J Med 2014; 370:632-9; PMID:24521109; http://dx.doi.org/10.1056/NEJMoa1311084
  • Ring T. Eculizumab in Atypical Hemolytic–Uremic Syndrome. N Engl J Med 2013; 369: 1377-80; PMID:24088106; http://dx.doi.org/10.1056/NEJMc1308826
  • Jaskowski TD, Martins TB, Litwin CM, Hill HR. Comparison of three different methods for measuring classical pathway complement activity. Clin Diagn Lab Immunol 1999; 6:137-9; PMID:9874678
  • Reiss U, Schwartz J, Sakamoto K, Puthenveetil G, Ogawa M, Bedrosian CL, Ware RE. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria: Eculizumab in Children with PNH. Pediatr Blood Cancer 2014; 61:1544-50; PMID:24777716; http://dx.doi.org/10.1002/pbc.25068
  • Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014; 12: 1440-8; PMID:24853860; http://dx.doi.org/10.1111/jth.12615
  • Delmas Y, Bordes C, Loirat C, Fremeaux-Bacchi V, Combe C. Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 2013; 6: 243-4; PMID:26019860; http://dx.doi.org/10.1093/ckj/sfs185
  • Gibiansky L, Gibiansky E. Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis. J Pharmacokinet Pharmacodyn 2009; 36: 341-51; PMID:19578985; http://dx.doi.org/10.1007/s10928-009-9125-9
  • Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633-59; PMID:20818831; http://dx.doi.org/10.2165/11535960-000000000-00000

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.